Insulet Stock

Insulet Revenue

The The revenue of Insulet (PODD) as of Aug 21, 2026 is 2.71 B USD. In the previous year, The revenue was 2.07 B USD — a change of 30.73% (higher).

Revenue

2.71 BUSD

YoY

30.73%

Last updated:

In 2026, Insulet's sales reached 2.71 B USD, a 30.73% difference from the 2.07 B USD sales recorded in the previous year.

Revenue has compounded at 41.6% per year over the past 19 years to 2.71 B USD.

The Insulet Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

REVENUE (B USD)
GROSS MARGIN (%)
Date
REVENUE (B USD)
GROSS MARGIN (%)
Jan 1, 2023
1.70 base
68.35 base
Jan 1, 2024
2.07 base
69.79 base
Jan 1, 2025
2.71 base
71.63 base
Jan 1, 2026 (e)
3.29 base
58.96 base
Jan 1, 2027 (e)
3.75 base
51.68 base
Jan 1, 2028 (e)
4.66 base
41.62 base
Jan 1, 2029 (e)
5.44 base
35.69 base
Jan 1, 2030 (e)
6.10 base
31.78 base
YEARREVENUE (B USD)GROSS MARGIN (%)
2030 est 6.1031.78
2029 est 5.4435.69
2028 est 4.6641.62
2027 est 3.7551.68
2026 est 3.2958.96
2025 2.7171.63
2024 2.0769.79
2023 1.7068.35
2022 1.3161.72
2021 1.1068.45
2020 0.9064.39
2019 0.7465.06
2018 0.5665.65
2017 0.4659.76
2016 0.3757.52
2015 0.2650.50
2014 0.2949.63
2013 0.2545.49
2012 0.2143.68
2011 0.1543.82
2010 0.1045.09
2009 0.0727.71
2008 0.04-12.71
2007 0.01-92.44
2006 0.00-327.52
Access this data via the Eulerpool API

Insulet Revenue

Insulet Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
1.70 B USD
220.00 M USD
206.30 M USD
Jan 1, 2024
2.07 B USD
308.90 M USD
418.30 M USD
Jan 1, 2025
2.71 B USD
473.80 M USD
247.10 M USD
Jan 1, 2026 (e)
3.29 B USD
384.30 M USD
467.90 M USD
Jan 1, 2027 (e)
3.75 B USD
454.96 M USD
555.61 M USD
Jan 1, 2028 (e)
4.66 B USD
538.82 M USD
726.37 M USD
Jan 1, 2029 (e)
5.44 B USD
628.33 M USD
877.48 M USD
Jan 1, 2030 (e)
6.10 B USD
705.57 M USD
1.03 B USD

Insulet Margins

Insulet stock margins

The Insulet margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Insulet. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Insulet.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
68.35 %
12.96 %
12.16 %
Jan 1, 2024
69.79 %
14.91 %
20.19 %
Jan 1, 2025
71.63 %
17.50 %
9.12 %
Jan 1, 2026 (e)
71.63 %
11.68 %
14.22 %
Jan 1, 2027 (e)
71.63 %
12.12 %
14.80 %
Jan 1, 2028 (e)
71.63 %
11.56 %
15.58 %
Jan 1, 2029 (e)
71.63 %
11.56 %
16.14 %
Jan 1, 2030 (e)
71.63 %
11.56 %
16.89 %

Insulet Stock analysis

What does Insulet do? Insulet Corp is an American company that was founded in 2000 and is headquartered in Acton, Massachusetts. Its goal is to improve the quality of life for people with diabetes by developing innovative products that make living with this chronic disease easier. Insulet Corp is known for its product "OmniPod." The OmniPod is a wireless, portable disposable insulin pump system that offers an alternative option to traditional pumping and insulin delivery systems. The OmniPod system consists of two small devices: a pod worn on the skin and a PDM (Personal Diabetes Manager) that regulates insulin delivery. The pod contains an insulin reservoir that communicates wirelessly with the PDM. The insulin dose is administered directly into the body without needles or tubes. Insulet Corp is also introducing the "OmniPod DASH System." This new system combines the proven design of the OmniPod pod with a new color touchscreen handheld device that allows for even easier operation. The DASH system also offers the ability to control insulin dosing from a smartphone, which can be taken with diabetics wherever they go. The success of the OmniPod system has made Insulet Corp a leading company in the diabetes industry. The company has also developed and introduced products and services in other areas of diabetes treatment. Insulet Corp has developed another product called "Amigo." This product is a personalized travel and training program for people who require insulin. Amigo offers specialized and personalized training to support diabetics in managing complex situations. It also offers diet and exercise plans to make living with diabetes easier. Insulet Corp has also developed a software called "OmniPod Horizon." This software is a closed-loop system that automatically adjusts insulin dosing to keep blood sugar levels within the target range. The system is currently in the development phase and is expected to be released in 2020. Insulet Corp has also developed a program called the "OmniPod Partner Program," which targets doctors and pharmacists. The program provides training and educational materials for healthcare providers to help them better treat and manage their patients. Since 2009, Insulet Corp has been listed on the NASDAQ stock exchange and has continuously evolved since then. The company currently has over 1500 employees and operates in North America, Europe, and the Middle East. Insulet Corp is a company focused on the development of innovative, life-changing products and services. It is expected to continue to play a significant role in improving the quality of life for people with diabetes in the future. Insulet is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Insulet's Sales Figures

The sales figures of Insulet originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Insulet’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Insulet's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Insulet’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Insulet stock

The revenue of Insulet is 2.71 B USD in 2026.

The revenue of Insulet changed from 2.07 B USD to 2.71 B USD, representing a 30.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The revenue Insulet since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Insulet historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Insulet

All Key Metrics — Insulet